StreetAlpha.app
Home › Stocks › SRPT

Sarepta Therapeutics, Inc. (SRPT)

Healthcare
$14.77
▼ −2.38%
LAST CLOSE · NOV 17

Sarepta Therapeutics develops and sells gene therapy and other medicines for genetic diseases. It last closed at $14.77 on Nov 17, down 2.38% on the day. The average 12-month price target from 2 analysts is $19.00 (+28.6% from the last close), with a high of $20.00 and a low of $18.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in SRPT, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is SRPT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.0B
−18.9% vs a year ago
Net income
−$114.6M
−5.9% margin
EPS (diluted)
−$1.29
Free cash flow
$176.4M
9.0% margin
Valuation
Market cap
$1.6B
107.2M shares
P/E
–
No P/E while losing money
Price to sales
0.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$472.8M
At Sep 30
Debt
$857.4M
At Sep 30
Shareholder equity
$1.5B
Shares outstanding
107.2M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $701.9M$701.9MFY2021FY2022: $933.0M$933.0MFY2022FY2023: $1.2B$1.2BFY2023FY2024: $1.9B$1.9BFY2024FY2025: $2.2B$2.2BFY2025

From SRPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Hold
2firms
0 Buy2 Hold0 Sell
Only 2 firms rated SRPT in the past 90 days, not enough for a consensus
Average 12-month target
$19.00
▲ 28.6% upside

Based on 2 analysts who set a price target on SRPT in the past 90 days. The average target is $19.00, with a high of $20.00 and a low of $18.00, compared with the last close of $14.77.

$14$17$21$24PAST 14 TRADING DAYS12-MONTH TARGETSHIGH $20AVG $19LOW $18Jun 17LAST CLOSE+12 MO$14$17$21$24PAST 14 DAYSTARGETSHIGH $20AVG $19LOW $18Jun 17LAST CLOSE+12 MO
Highest target$20.00
Average target$19.00
Lowest target$18.00
Latest rating changes
RBC CapitalTarget raised
Nov 6Hold$17 → $18
RBC CapitalMaintained
Oct 8Hold$17
JP MorganMaintained
Sep 30Hold$20
Piper SandlerMaintained
Jul 9Hold$20
Wolfe ResearchUpgrade
Jul 9Buy$27
DateFirmActionRatingPrice target
Nov 6RBC CapitalTarget raisedHold$17 → $18
Oct 8RBC CapitalMaintainedHold$17
Sep 30JP MorganMaintainedHold$20
Jul 9Piper SandlerMaintainedHold$20
Jul 9Wolfe ResearchUpgradeBuy$27
Loading…

Technical Analysis

SRPT · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 19% below its 20 day and 24% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the swing low (Aug 3) at $14.75, and the nearest resistance the Pivot at $14.82.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.2%/day
Key levels
$24.6852 week high+67.1%
$18.46200 day average+25.0%
$18.3250 day average+24.0%
$18.30100 day average+23.9%
$17.6020 day average+19.2%
$16.69Swing high (Jul 27)+13.0%
$15.07Pivot R1+2.0%
$14.82Pivot+0.3%
$14.77Last close
$14.75Swing low (Aug 3)−0.1%
$14.5852 week low−1.3%
$14.52Pivot S1−1.7%
Indicators
RSI (14)31.20Weak, oversold below 30Neutral
MACD-0.78Below its signal lineBearish
Stochastic4.8Near the bottom of its rangeOversold
ADX (14)18.8No clear trend
Williams %R-96.3Oversold below −80, overbought above −20Oversold
CCI (20)-179.1Oversold below −100, overbought above 100Oversold
Rate of change−20.3%Change over 10 sessionsBearish
ATR (14)$0.91Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SRPT

What happened before

See how SRPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SRPT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SRPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 24 – Sep 24
Loading…

See today’s whale options flow across the market →

SRPT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼135 buying vs 168 selling
  • ▼Held by funds -2.9 pts
  • ▼Funds holding -20
  • ●Superinvestors: 2 added, 2 cut
  • ▲Put/call 5.80 to 0.95
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding311331−6.0%
In funds' top 1000–
Held by funds99.7%102.5%−2.9 pts
New / increased38 / 9747 / 101−8.8%
Reduced / sold out113 / 55118 / 68−9.7%
Put/call ratio0.955.80−83.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SRPT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRPT is in one of them and how their past SRPT trades turned out.

SRPT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SRPT in an article yet. Here's the latest on the wider market.

SRPT Congress Trades

All congress trades →
Trades, 12 months
3
Buys
1
33%
Sells
2
67%
People
1
Last filed Sep 22
Who traded SRPT · since 2019
Latest 5 filings of 21
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$1K – $15KTraded Mar 30, 2026Filed May 14, 2026
$15K – $50KTraded Mar 4, 2026Filed May 14, 2026
$1K – $15KTraded Apr 14, 2025Filed May 7, 2025
$1K – $15KTraded Apr 13, 2025Filed May 5, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$1K – $15KMar 30, 2026May 14, 202645 d
Donald J TrumpExecutive branchBuy$15K – $50KMar 4, 2026May 14, 202671 d
Gilbert CisnerosD · CASell$1K – $15KApr 14, 2025May 7, 202523 d
Gilbert CisnerosD · CASell$1K – $15KApr 13, 2025May 5, 202522 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts. It develops and sells gene therapy and other medicines for genetic diseases. One of its products, ELEVIDYS, is a gene therapy given to patients through infusion centers. Its customers include patients, specialist physicians, healthcare providers and payers that cover the cost of treatment.

Headquarters
Cambridge, MA
Founded
1980